Biopure Submits Hemopure Application In The U.K.
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it targeted the United Kingdom before the rest of the EU because of the country's "unique blood banking issues."
You may also be interested in...
Biopure’s Hemopure BPAC Review To Be Closed-Door
The day before Biopure's July 14 review, FDA's Blood Products Advisory Committee will discuss Nabi's Nabi-HB immunoglobulin for hepatitis B.
Biopure To Develop Hemopure As Cardioprotective Agent Under Restructuring
The company has established a cardiology medical advisory board under the direction of new CEO Zafiris Zafirelis. Biopure expects that data from FDA-requested animal studies will allow it to move forward with U.S. clinical trials for cardiac ischemia.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.